Peter Ettmayer

Peter Ettmayer is a distinguished medicinal chemist at Boehringer Ingelheim with more than two decades of expertise in covalent inhibitor design and allosteric kinase modulator development. His group at Boehringer has been instrumental in advancing the chemistry of allosteric kinase inhibitors — compounds that bind outside the ATP-competitive active site to lock kinases in inactive conformations — including programs targeting MEK, SHP2, and mutant KRAS. Ettmayer has contributed significantly to the chemical optimization of irreversible and reversible covalent inhibitors through systematic studies of warhead reactivity, selectivity, and protein residence time, informing the design of compounds with improved therapeutic windows. In KRAS drug development, his team contributed to allosteric pocket characterization (Switch I/II pocket) and covalent-allosteric inhibitor design strategies that complemented parallel work on KRAS G12C covalent inhibitors. His research has also advanced prodrug strategies for enhancing cancer drug delivery, including work on linker design for tumor-targeted releasing systems. With over 200 peer-reviewed publications and extensive patent portfolios in oncology drug design, Ettmayer represents the high-level industrial research expertise that bridges academic chemical biology insights to regulatory-quality drug candidates.